Castleview Partners’s iShares Biotechnology ETF IBB Stock Holding History

Castleview Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28	Closed	-$3.84K	–	710
2024 Q2	$3.84K	Hold	28	–	–	﹤0.01%	656
2024 Q1	$3.84K	Hold	28	–	–	﹤0.01%	671
2023 Q4	$3.8K	Sell	28 -1,593	-98%	-$194K	﹤0.01%	616
2023 Q3	$198K	Sell	1,621 -33	-2%	-$4.2K	0.18%	114
2023 Q2	$210K	Buy	1,654 +605	+58%	+$78.6K	0.19%	108
2023 Q1	$135K	Buy	1,049 +1,021	+3,646%	+$134K	0.12%	149
2022 Q4	$3.68K	Hold	28	–	–	﹤0.01%	469
2022 Q3	$3K	Buy	28 +23	+460%	+$2.86K	﹤0.01%	494
2022 Q2	$328	Sell	5 -23	-82%	-$2.73K	﹤0.01%	732
2022 Q1	$3K	Sell	28 -25,306	-100%	-$3.3M	﹤0.01%	613
2021 Q4	$166	Buy	+25,334	New	+$3.92M	﹤0.01%	715
2021 Q2	$27K	Buy	+166	New	+$25.6K	0.01%	511
2018 Q1	$440K	Buy	+4,120	New	+$457K	0.36%	62

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Castleview Partners's IBB Position: Q3 2024 in Review

Castleview Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2024, closing a stake of 28 shares — an estimated $3.84K sold.

Castleview Partners first reported a position in IBB in Q1 2018 and held it in 13 quarters. The position peaked at $440K in Q1 2018. 893 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

Castleview Partners reported no remaining iShares Biotechnology ETF position as of Q3 2024 after selling out during the quarter.
Castleview Partners sold 28 iShares Biotechnology ETF shares in Q3 2024, an estimated $3.84K.
Castleview Partners first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 13 quarters.
Castleview Partners's iShares Biotechnology ETF position peaked at $440K in Q1 2018.
893 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.